

Commissioner for Patents Washington, DC 20231 www.uspto.gov

FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER APPLICATION NUMBER 214683

09/998,350

LEYDIG VOIT & MAYER, LTD

180 NORTH STETSON AVENUE CHICAGO, IL 60601-6780

TWO PRUDENTIAL PLAZA, SUITE 4900

23460

11/30/2001

Peter P. Roller

**CONFIRMATION NO. 5514** 

**FORMALITIES LETTER** 

\*OC000000008903732\*

Date Mailed: 10/03/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE





## PATENT Attorney Docket No. 214683 DHHS Ref. E-081-99/1

Group Art Unit: Unassigned

Examiner: Unassigned

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Roller et al.

Application No. 09/998,350

Filed: November 30, 2001

For: REDOX-STABLE, NON-

PHOSPHORYLATED CYCLIC PEPTIDE INHIBITORS OF SH2 DOMAIN BINDING TO TARGET

PROTEIN, CONJUGATES

THEREOF, COMPOSITIONS AND METHODS OF SYNTHESIS AND

USE

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Dear Sir:

In Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated October 3, 2002, a sequence listing is being submitted as part of the patent application. The sequence listing is in the form of both a paper copy and a computer readable copy on a computer diskette. The undersigned hereby verifies that the content of the paper copy and the computer readable copy, as concurrently being submitted, are the same and do not introduce new matter.

Respectfully submitted.

Carol Larcher, Reg. No. 35,243 LEYDIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780 (312) 616-5600 (telephone)

(312) 616-5700 (facsimile)

Date: December 3, 2002

In re Appln. of Roller et al. U.S. Patent Appln. No. 09/998,350

**CERTIFICATE OF MAILING** 

DEC 0 9 2002 hereby certify that this RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEURASE OUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (along with any referred to as being attached or enclosed) is being deposited with the United to a second s documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

Date: Dr. 3, 2002 Ellen K. Manl